JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

CTLA-4, LAG-3, TIGIT & Other Checkpoints

Checkpoint antibodies in this group block inhibitory immune receptors other than PD-1 on T cells and other lymphocytes. Ipilimumab and tremelimumab bind cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and prevent its competition with CD28 for B7 ligands. Relatlimab targets lymphocyte-activation gene 3 (LAG-3), and tiragolumab targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT). Sabatolimab and cobolimab bind T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) on T cells and myeloid cells. Further antibodies cover B7-H3, B7-H4, VISTA, BTLA, PVRIG and the adenosine-pathway enzymes CD39 and CD73.

Cat. No.

AT0186

CAS No.

2378407-27-1

Uliledlimab

Synonyms: TJ004309

Uliledlimab is a humanized monoclonal antibody that targets CD73, exhibiting potent inhibitory activity. This antibody effectively blocks the enzymatic conversion of extracellular adenosine monophosphate (AMP) to adenosine, a mechanism implicated in tumor evasion of immune surveillance. Uliledlimab is primarily utilized in cancer research, where it serves as a critical tool for studying the role of the adenosine pathway in tumor progression and response to therapy.

In stock View Details

1 mg

$328.00

5 mg

$704.00

All 3 sizes

CTLA-4, LAG-3, TIGIT & Other Checkpoints

Uliledlimab